Trulieve Cannabis Corp. TRUL TCNNF announced Monday it will buy Harvest Health & Recreation Inc. HARV HRVSF for a whopping $2.1 billion in an all-stock deal.
Under the merger agreement, Harvest shareholders will acquire 0.1170 of subordinate voting shares of Trulieve for each Harvest share priced at $4.79. Upon completing the merger, Harvest shareholders should hold roughly 26.7% of Trulieve’s issued and outstanding pro forma shares (on a fully diluted basis).
The Analyst
Cantor Fitzgerald’s Pablo Zuanic kept an ‘Overweight’ rating on Trulieve’s stock but lowered the price target to $76 from $89.
The Thesis
Changes to the price target were necessary in response to the new merger and increased share count to 181 million, explained Zaunic in a Monday note.
As the company begins to look more like a real multi-state operator, instead of a single-state operator (per estimates, Florida accounted for more than 90% of Trulieve’s sales last year), the analyst says “the stock should rerate.”
Although Harvest wouldn’t have been their first choice, Zuanic said that they are aware that via the merger, Trulieve will obtain #1 status in Arizona, get close to being #1 in Pennsylvania and further advance its outreach across Florida.
And while it could be argued that another approach, such as asset collection, would be less expansive, and that reaching other key states such as New Jersey and New York could bring more benefits in the long term, Zuanic confirms that Harvest “is a fully-fledged operation with intrinsic value beyond just assets.”
Trulieve should continue its expansion via mergers and acquisitions as well as find ways to reach important markets like New Jersey and New York, the analyst added.
The Florida-based cannabis company is scheduled to report its first-quarter earnings this Thursday, after which Zuanic plans to update Cantor Fitzgerald's model to proforma terms.
The Price Action
Trulieve’s shares were trading 3.37% lower at $37.31 per share at the time of writing.
Photo by Esteban Lopez on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.